Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1
Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis worldwide. IgAN is
progressive, particularly when patients have a significant proteinuria (proteinuria >1g/g
creatinine), impaired kidney function, or elevated blood pressure. In 10 years, nearly 20-40%
of these IgAN patients progress to end-stage renal disease (ESRD). Early IgAN is tentatively
defined when proteinuria is insignificant and kidney function and blood pressure are normal.
Patients with early IgAN rarely progress to ESRD. However, 30-40% of patients with early IgAN
ultimately developed a significant proteinuria and hypertension in 10 years. Therefore,
earlier intervention may be needed if it can prevent the development of a significant
proteinuria and hypertension. Since angiotensin ll receptor blocker (ARB) is drug of choice
in reducing proteinuria and controlling blood pressure, the investigators hypothesized that
early introduction of ARB may be beneficial in preventing the significant proteinuria
development in early IgAN patients. To prove the hypothesis, the investigators plan the
current interventional study.
Phase:
Phase 3
Details
Lead Sponsor:
Ewha Womans University
Collaborators:
Ajou University School of Medicine Chonbuk National University Hospital Chonnam National University Hospital Eulji General Hospital Gangnam Severance Hospital Hallym University Medical Center Kangdong Sacred Heart Hospital Korea University Guro Hospital Kyung Hee University Hospital at Gangdong Kyungpook National University Kyungpook National University Hospital National Health Insurance Service Ilsan Hospital Pusan National University Yangsan Hospital Seoul National University Bundang Hospital Seoul National University Hospital Severance Hospital SMG-SNU Boramae Medical Center The Catholic University of Korea
Treatments:
Antibodies Immunoglobulin A Immunoglobulins Losartan